Mark A. Socinski, MD

All articles by Mark A. Socinski, MD

Oncologists who care for NSCLC patients need to develop management strategies.

From The Advisory Board

Improving Survival in Advanced NSCLC: Multiple Lines of Chemotherapy Make a Difference

Mark A. Socinski, MD

September 30, 2014

Oncologists who care for non-small cell lung cancer (NSCLC) patients need to develop management strategies.

Lung Cancer

Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy for NSCLC

Mark A. Socinski, MD

March 18, 2013

Editorial Advisory Board member Dr. Socinski discusses the key clinical insights brought to light by the POINTBREAK trial, presented at the 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology.

From The Advisory Board

Crizotinib Treatment in ROS1-positive NSCLC Patients: A Case Study

Mark A. Socinski, MD

May 1, 2012

Although prevalence of cytogenetic abnormality in tumor biopsy is low, finding one or more abnormalities can expand the patient’s treatment options.

Next post in From The Advisory Board

Mark A. Socinski, MD

All articles by Mark A. Socinski, MD

Improving Survival in Advanced NSCLC: Multiple Lines of Chemotherapy Make a Difference

Q&A with Mark Socinski, MD, on the POINTBREAK Trial of Maintenance Therapy for NSCLC

Crizotinib Treatment in ROS1-positive NSCLC Patients: A Case Study

Treatment Options Emerge for Metastatic Castrate Resistant Prostate Cancer